---
created: 2025-04-13
updated: 2025-04-13T10:52
id: tsH!V->_6S
specialty: immuno
specialty_id: 104
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::12-immunology::03-pharm::02-immunosuppressive-drugs
  - "source/ak-step1-v11:": 
  - theme/b&b::16-pathology::08-granulomatous-inflammation
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::infliximab
  - "source/ak-step1-v11:": 
  - theme/firstaid::11-musculoskeletal-skin-connective-tissue::04-pharm::10-tnf-a-inhibitors
  - "source/ak-step1-v11:": 
  - theme/firstaid::11-musculoskeletal-skin-connective-tissue::04-pharm::10-tnf-a-inhibitors::infliximab
  - "source/ak-step1-v11:": 
  - theme/ome::07-immunology::16-immunosuppression
  - "source/ak-step1-v11:": 
  - source/ome-banner::clinical::08-rheumatology::03-rheumatoid-arthritis
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::09-musculoskeletal::09-tnf-alpha-inhibitors
  - "source/ak-step1-v11:": 
  - theme/pixorize::01-immunology::05-cytokines::01-tnf-alpha
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::12-msk::tnf-inhibitors-(infliximab,-adalimumab.-certolizumab,-golimumab)
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::immunology-&-biochemistry-pharmacology::immuno-suppressives::general-immunotherapy
  - "source/ak-step1-v11:": 
  - theme/uworld::1000-9999::6000-6999::6513
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::14000-14999::14805
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield
  - "source/ak-step2-v11:": 
  - theme/ome::08-rheumatology::03-rheumatoid-arthritis
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::im::ome::rheum::ra
  - source/ak-step2-v11::original-decks::dorian::im::ome::rheum::ra"
type: flashcard
---

# Question
Infliximab, adalimumab is a monoclonal antibody against **TNF-Î±**

---

# Answer
"AntiDrug Antibodies (""ADA"") can develop x adalimumab; block its interaction with TNF-alpha, preventing the drug from functioning == more rapid drug clearance = declining effectiveness"